Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the ...

Aortic valve stenosis' is an often-overlooked condition and a growing health concern in ageing societies such as Thailand. With an increasing elderly population and a rise in age-related valve ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Results from the EARLY TAVR trial — the first randomized, controlled FDA pivotal study designed to determine the best ...

[18] While no medication has been shown to delay the progression of aortic stenosis, appropriate use of aspirin, angiotensin-converting enzyme inhibitors, blockers, and "statins" may decrease ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

A first-of-its-kind therapy successfully slowed plaque progression in patients with aortic stenosis. Ataciguat may reduce the need for surgical or transcatheter aortic valve replacement.

More information: Bin Zhang et al, Reactivation of Oxidized Soluble Guanylate Cyclase as a Novel Treatment Strategy to Slow ...

VPDs with very short coupling intervals developing during an acute stage of myocardial infarction would predict the ...

Researchers found that a gene on the Y chromosome influences how aortic valve stenosis progresses differently in males and ...

Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS ... further underscoring the rapid and unpredictable progression of the disease and urgency to refer ...